Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg Acquires 32,844 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) Director Beth C. Seidenberg acquired 32,844 shares of the company’s stock in a transaction on Wednesday, March 15th. The shares were acquired at an average price of $7.12 per share, for a total transaction of $233,849.28. Following the completion of the acquisition, the director now directly owns 1,770,227 shares in the company, valued at $12,604,016.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded down $0.13 during midday trading on Friday, reaching $7.13. 1,689,345 shares of the company traded hands, compared to its average volume of 990,133. Vera Therapeutics, Inc. has a twelve month low of $5.20 and a twelve month high of $24.94. The firm has a market capitalization of $197.22 million, a price-to-earnings ratio of -2.41 and a beta of -0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.85 and a quick ratio of 7.85. The company has a fifty day moving average price of $7.66 and a 200 day moving average price of $14.70.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. boosted its position in Vera Therapeutics by 29.2% during the 1st quarter. American International Group Inc. now owns 6,794 shares of the company’s stock valued at $160,000 after purchasing an additional 1,535 shares during the period. UBS Group AG acquired a new position in Vera Therapeutics during the 1st quarter valued at approximately $47,000. Northern Trust Corp boosted its position in Vera Therapeutics by 2.8% during the 2nd quarter. Northern Trust Corp now owns 112,470 shares of the company’s stock valued at $1,531,000 after purchasing an additional 3,063 shares during the period. Barclays PLC boosted its position in Vera Therapeutics by 32.5% during the 4th quarter. Barclays PLC now owns 13,279 shares of the company’s stock worth $256,000 after acquiring an additional 3,254 shares during the period. Finally, Legal & General Group Plc boosted its position in Vera Therapeutics by 274.8% during the 2nd quarter. Legal & General Group Plc now owns 4,898 shares of the company’s stock worth $67,000 after acquiring an additional 3,591 shares during the period. Institutional investors and hedge funds own 88.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on VERA shares. JPMorgan Chase & Co. lifted their target price on Vera Therapeutics from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, November 18th. Jefferies Financial Group lowered Vera Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $32.00 to $6.00 in a research report on Wednesday, January 4th. Wedbush lowered Vera Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $33.00 to $8.00 in a research report on Wednesday, January 4th. Finally, HC Wainwright decreased their target price on Vera Therapeutics from $36.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, January 4th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

About Vera Therapeutics

(Get Rating)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.